These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 9598479

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R, Tulchiner G, Fritz J, Schaefer G, Horninger W, Heidegger I.
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [Abstract] [Full Text] [Related]

  • 9. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP, FinnBladder Group.
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [Abstract] [Full Text] [Related]

  • 10. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder.
    Serretta V, Pomara G, Rizzo I, Esposito E.
    Eur Urol; 2000 Oct; 38(4):419-25. PubMed ID: 11025380
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
    Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS.
    J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A, Esposito N, Currò A, Biasoni D, Montanari E, Mangiarotti B, Trinchieri A, Zanetti G, Serrago MP, Pisani E.
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C.
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [Abstract] [Full Text] [Related]

  • 18. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
    Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A.
    Urology; 2000 Aug 01; 56(2):228-31. PubMed ID: 10925083
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.